Detailed positive results from the DESTINY-Breast06 phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low metastatic breast cancer and the overall trial population (patients with HR-positive, HER2-low and HER2-ultralow [defined as IHC 0 with membrane staining] expression) following one or more lines of endocrine therapy.
Researchers at Indiana University School of Medicine, Mayo Clinic, Washington University in St. Louis, the University of Pennsylvania, Columbia University, and Intel received a five-year, $3.7 million NCI grant for a multi-site study developing a privacy-preserving artificial intelligence approach—called federated learning—which aims to improve breast cancer risk prediction and reduce health inequities in cancer prevention care.
